Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
dc.contributor.author | Kamthan, A G | |
dc.contributor.author | Lind, Michael J | |
dc.contributor.author | Thatcher, Nick | |
dc.contributor.author | Steward, William P | |
dc.contributor.author | Bronchud, M H | |
dc.contributor.author | Ranson, Malcolm R | |
dc.contributor.author | Stout, Ronald | |
dc.date.accessioned | 2010-07-14T16:01:21Z | |
dc.date.available | 2010-07-14T16:01:21Z | |
dc.date.issued | 1990 | |
dc.identifier.citation | Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. 1990, 26 (6):691-4 Eur J Cancer | en |
dc.identifier.issn | 0959-8049 | |
dc.identifier.pmid | 2168191 | |
dc.identifier.uri | http://hdl.handle.net/10541/107648 | |
dc.description.abstract | 61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had 'limited stage' disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 with mesna on day 1, and etoposide 120 mg/m2 intravenously on days 1 and 2 and 240 mg/m2 orally on day 3. Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed. Complete response rate in limited stage patients was 55% and 16% in extensive stage patients. The partial responses were 38% and 66% respectively. Overall median survival was 10.5 months with 2-year survival of 14%. The corresponding values for limited stage disease were 13 months and 16% and for extensive stage disease 8 months and 13%. Despite the addition of doxorubicin at a somewhat higher dosage than usual in this type of regimen and a policy of no dose reduction, toxicity was generally mild. There was, however, a 19% relapse rate in complete responders in the brain, apparently as the sole site of disease. | |
dc.language.iso | en | en |
dc.subject | Lung Cancer | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Carcinoma, Small Cell | |
dc.subject.mesh | Doxorubicin | |
dc.subject.mesh | Etoposide | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Ifosfamide | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Prognosis | |
dc.title | Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. | en |
dc.type | Article | en |
dc.contributor.department | Department of Medical Oncology, Christie Hospital, Manchester, U.K. | en |
dc.identifier.journal | European Journal of Cancer | en |
html.description.abstract | 61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had 'limited stage' disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 with mesna on day 1, and etoposide 120 mg/m2 intravenously on days 1 and 2 and 240 mg/m2 orally on day 3. Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed. Complete response rate in limited stage patients was 55% and 16% in extensive stage patients. The partial responses were 38% and 66% respectively. Overall median survival was 10.5 months with 2-year survival of 14%. The corresponding values for limited stage disease were 13 months and 16% and for extensive stage disease 8 months and 13%. Despite the addition of doxorubicin at a somewhat higher dosage than usual in this type of regimen and a policy of no dose reduction, toxicity was generally mild. There was, however, a 19% relapse rate in complete responders in the brain, apparently as the sole site of disease. |